



Relay Therapeutics Names Deborah Palestrant, Ph.D., Vice President of Corporate Development and Strategy

CAMBRIDGE, Mass., July 24, 2017 -- [Relay Therapeutics](#), a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the appointment of Deborah Palestrant, Ph.D., MBA, to Vice President of Corporate Development and Strategy. Palestrant brings to Relay significant life sciences industry experience including drug discovery, company creation, operations, business development, and strategy.

“We are thrilled to welcome Deb to Relay,” said Sanjiv Patel, President and CEO of Relay Therapeutics. “Deb’s impressive track record of business development, coupled with her commitment to building transformative platform companies that impact patients, make her an outstanding fit as we continue to build Relay and develop our partnering strategy.”

Prior to joining Relay, Palestrant led the business development team at Editas Medicine from its inception. As a senior associate at Third Rock Ventures, she helped to conceive and launch Editas and was part of the original founding team. She also, while at Third Rock Ventures, helped to launch and build Blueprint Medicines.

Palestrant received her Ph.D. from Columbia University in biochemistry and molecular biophysics. She was a Damon Runyon Cancer Research Foundation Postdoctoral Fellow at The Scripps Research Institute, and a structural biologist at the Novartis Institutes for Biomedical Research. She earned an MBA from Northeastern University.

About Relay Therapeutics

Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach and by focusing on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016 with \$57 million in Series A financing from Third Rock Ventures and an affiliate of D. E. Shaw Research.

###

Media Contact:
Katie Engleman
Pure Communications, Inc.
(910) 509-3977

Katie@purecommunicationsinc.com